- Home
- SCPH vs LYEL Comparison
SCPH vs LYEL Comparison
Compare SCPH & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCPH
- LYEL
- Stock Information
- Founded
- SCPH 2013
- LYEL 2018
- Country
- SCPH United States
- LYEL United States
- Employees
- SCPH N/A
- LYEL N/A
- Industry
- SCPH Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- SCPH Health Care
- LYEL Health Care
- Exchange
- SCPH Nasdaq
- LYEL Nasdaq
- Market Cap
- SCPH 173.6M
- LYEL 207.7M
- IPO Year
- SCPH 2017
- LYEL 2021
- Fundamental
- Price
- SCPH $4.51
- LYEL $9.84
- Analyst Decision
- SCPH Strong Buy
- LYEL Sell
- Analyst Count
- SCPH 3
- LYEL 2
- Target Price
- SCPH $14.00
- LYEL $15.00
- AVG Volume (30 Days)
- SCPH 261.6K
- LYEL 148.8K
- Earning Date
- SCPH 08-13-2025
- LYEL 08-06-2025
- Dividend Yield
- SCPH N/A
- LYEL N/A
- EPS Growth
- SCPH N/A
- LYEL N/A
- EPS
- SCPH N/A
- LYEL N/A
- Revenue
- SCPH $41,982,000.00
- LYEL $65,000.00
- Revenue This Year
- SCPH $108.95
- LYEL N/A
- Revenue Next Year
- SCPH $73.83
- LYEL N/A
- P/E Ratio
- SCPH N/A
- LYEL N/A
- Revenue Growth
- SCPH 138.10
- LYEL N/A
- 52 Week Low
- SCPH $1.94
- LYEL $7.65
- 52 Week High
- SCPH $5.65
- LYEL $38.40
- Technical
- Relative Strength Index (RSI)
- SCPH 60.01
- LYEL 52.64
- Support Level
- SCPH $3.83
- LYEL $9.11
- Resistance Level
- SCPH $4.18
- LYEL $10.41
- Average True Range (ATR)
- SCPH 0.17
- LYEL 0.61
- MACD
- SCPH -0.02
- LYEL 0.04
- Stochastic Oscillator
- SCPH 76.60
- LYEL 70.77
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.